source
- Telix to acquire Germany's ITM for $1.65 billion, aiming to dominate radiopharmaceutical marketTelix, an Australian radiopharmaceutical diagnostics company, announced it will purchase German developer ITM in a cash transaction valued at $1.65 billion upfront. The agreement gives Telix the o…
- Experts see Replimune’s Tudriqev approval as a step toward broader use of localized cancer therapiesReplimune received FDA approval last month for Tudriqev, an oncolytic virus injected directly into melanoma tumors, marking only the second such approval for a therapy delivered straight into a tum…